[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SLC17A1

Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Apical cell membrane Multi-pass membrane protein
Domain PF07690 Major Facilitator Superfamily
Function

Important for the resorption of phosphate by the kidney. May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Plays a role in urate transport in the kidney (PubMed:27906618).

> Gene Ontology
 
Biological Process GO:0006814 sodium ion transport
GO:0006817 phosphate ion transport
GO:0006820 anion transport
GO:0015672 monovalent inorganic cation transport
GO:0015698 inorganic anion transport
GO:0035435 phosphate ion transmembrane transport
GO:0035725 sodium ion transmembrane transport
GO:0044341 sodium-dependent phosphate transport
GO:0046415 urate metabolic process
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
Molecular Function GO:0005436 sodium:phosphate symporter activity
GO:0008509 anion transmembrane transporter activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015114 phosphate ion transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015296 anion:cation symporter activity
GO:0015321 sodium-dependent phosphate transmembrane transporter activity
GO:0022804 active transmembrane transporter activity
GO:0022853 active ion transmembrane transporter activity
GO:0046873 metal ion transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-425374: Amino acid and oligopeptide SLC transporters
R-HSA-428643: Organic anion transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC17A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC17A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC17A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1560.404
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0050.992
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2770.539
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0630.946
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2930.831
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2120.887
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1920.899
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8330.664
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8560.00803
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC17A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.79.6-5.90.679
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.711.9-8.20.426
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC17A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC17A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC17A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC17A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC17A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC17A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC17A1
Namesolute carrier family 17 (organic anion transporter), member 1
Aliases NAPI-1; NPT1; solute carrier family 17 (sodium phosphate), member 1; NPT-1; Na(+)/PI cotransporter 1; na/Pi- ......
Chromosomal Location6p22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC17A1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.